A variety of GLP-1 drugs that were developed to treat Type 2 diabetes, including Novo Nordisk’s Ozempic, have secured label ...

The Covid-19 pandemic turned Moderna and BioNTech into household names almost overnight. Now the two companies find ...

On a tumultuous trading day, Eli Lilly and Co. (LLY) showcased a dramatic stock performance that belied its closing uptick. Starting the day with high hopes, the stock surged to a peak before plunging ...

Eli Lilly said on Thursday that its newer diabetes drug Mounjaro outperformed Trulicity, its previously top-selling ...

DelveInsight's THR-β Agonist Market Size, Target Population, Competitive Landscape & Market Forecast report includes a ...

Hit by rising medical care costs and squeezed by government changes, the health care conglomerate acknowledges “pricing and operational mistakes” affected its bottom line and has outlined steps to ...

The FTSE 100 tracked about a third of a per cent lower this morning amid with another stack of earnings to digest and a key three days in the US likely to set the tone. The S&P 500 slid 0.3 per cent ...

The global Plant Derived Proteins Market is on a significant growth trajectory, estimated to reach USD 184.3 Million by 2029, up from USD 105 Million in 2022. This robust expansion, projected at an 8.

Eli Lilly's stock took a noticeable dip following a guidance update from rival Novo Nordisk. Investors reacted sharply as ...

This peer was Novo Nordisk, which like Eli Lilly sells a popular drug approved specifically for obesity. Eli Lilly's recent popularity is due in no small measure to its plunge into the highly ...

The newest BTK inhibitor on the market, Eli Lilly’s Jaypirca, has s | In a phase 3 trial, the newest Bruton’s tyrosine kinase inhibitor on the market, Eli Lilly’s Jaypirca, has shown its chops in a ...